Announcements Trials

Browse Landscape

Phase

Phase 1 12 Phase 2 6 Phase 1/2 1

Status

Sponsor Class

NIH 2 OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 1

Interventions

pembrolizumab 242 Carboplatin 137 Nivolumab 132 Gemcitabine 127 Paclitaxel 116 Cisplatin 105 Cyclophosphamide 97 Bevacizumab 93 Dexamethasone 78 Injections 75 Pemetrexed 71 Docetaxel 71 Fluorouracil 68 Capecitabine 65 Rituximab 61 Cetuximab 61 atezolizumab 59 130-nm albumin-bound paclitaxel 59 Oxaliplatin 58 Leucovorin 57 Ipilimumab 54 fludarabine 50 Lenalidomide 47 Azacitidine 40 Irinotecan 39 venetoclax 38 Fulvestrant 38 Albumin-Bound Paclitaxel 36 Prednisone 35 Trastuzumab 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × INDUSTRY × adavosertib × Clear all

NCT01076400 2023-09-18

MK-1775-008

Merck Sharp & Dohme LLC

Phase 1/2 Terminated

7 enrolled 6 charts

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡